Treatment of Severe and Fulminnant Clostridioides difficile Infection
Purpose of review
This article will review current management strategies for severe and fulminant Clostridioides difficile infection (CDI).
Clostridioides difficile is the most common nosocomial cause of infectious diarrhea. With the rise of hypervirulent strains of CDI, almost 8% of patients hospitalized with CDI are afflicted with severe CDI (SCDI) or fulminant CDI (FCDI). A significant proportion of these patients do not respond to recommended anti-CDI antibiotic therapy such as oral vancomycin and fidaxomicin. Current recommendations suggest that patients with refractory CDI should proceed to colectomy or diverting loop ileostomy with colonic lavage. However, both of these surgical interventions result in high rates of post-surgical mortality approaching 30%. Fecal microbiota transplantation (FMT) is a promising therapy that is recommended in recurrent CDI. Recent studies have found that FMT can safely produce cure rates between 70 and 90% in patients with SCDI and FCDI, while significantly decreasing rates of CDI-related mortality and colectomy. A patient population likely to benefit the most from FMT is elderly patients due to their increased risk for CDI, treatment failure, and high comorbidity burden that may preclude surgical intervention.
FMT should be considered in patients with SCDI or FCDI particularly when traditional anti-CDI antibiotics are ineffective.
KeywordsFecal microbiota transplantation Elderly Aged Clostridioides difficile Inflammatory bowel disease Colonoscopy
Compliance with ethical standards
Conflict of interest
Yao-Wen Cheng declares that he has no conflict of interest. Monika Fischer declares that she has no conflict of interest.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as:• Of importance ••Of major importance
- 4.McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.PubMedPubMedCentralCrossRefGoogle Scholar
- 5.Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald L, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedCrossRefPubMedCentralGoogle Scholar
- 18.Stevens VW, Nelson RE, Schwab-Daugherty EM, Khader K, Jones MM, Brown KA, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med. 2017;177(4):546–53.PubMedCrossRefPubMedCentralGoogle Scholar
- 21.Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69(11):2892–900.PubMedCrossRefPubMedCentralGoogle Scholar
- 24.Rokas KE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis. 2015;61(6):934–41.PubMedCrossRefPubMedCentralGoogle Scholar
- 28.Coffman K, Chen XJ, Okamura C, Louie E. IVIG–A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and fidaxomicin. IDCases. 2017;8:27–8.PubMedPubMedCentralCrossRefGoogle Scholar
- 36.Fashandi AZ, Martin AN, Wang PT, Hedrick TL, Friel CM, Smith PW, et al. An institutional comparison of total abdominal colectomy and diverting loop ileostomy and colonic lavage in the treatment of severe, complicated Clostridium difficile infections. Am J Surg. 2017;213(3):507–11.PubMedCrossRefPubMedCentralGoogle Scholar
- 44.Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2402–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 47.Cheng, Y. W., E. Phelps, V. Ganapini, N. Khan, F. Ouyang, H. Xu, S. Khanna, R. Tariq, R. J. Friedman-Moraco, M. H. Woodworth, T. Dhere, C. S. Kraft, D. Kao, J. Smith, L. Le, N. El-Nachef, N. Kaur, S. Kowsika, A. Ehrlich, M. Smith, N. Safdar, E. A. Misch, J. R. Allegretti, A. Flynn, Z. Kassam, A. Sharfuddin, R. Vuppalanchi, and M. Fischer. 2019. "Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience." Am J Transplant 19 (2):501-511. https://doi.org/10.1111/ajt.15058.PubMedCrossRefPubMedCentralGoogle Scholar
- 51.• Allegretti JR, et al. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc. 2018;87(1):18–29. Clinically-focused discussion of patient/donor selection for FMT and infrastructure necessary for delivery.PubMedCrossRefPubMedCentralGoogle Scholar
- 54.Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. 2016;50(5):403–7.PubMedPubMedCentralGoogle Scholar
- 56.•• Fischer M, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42(4):470–6. Describes a sequential FMT protocol with high rates of success in patients with SCDI and FCDI.PubMedCrossRefPubMedCentralGoogle Scholar
- 58.Fischer, M., B. Sipe, Y. W. Cheng, E. Phelps, N. Rogers, S. Sagi, M. Bohm, H. Xu, and Z. Kassam. 2017. "Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach." Gut Microbes 8 (3):289-302. https://doi.org/10.1080/19490976.2016.1273998.PubMedPubMedCentralCrossRefGoogle Scholar
- 59.Ianiro G, Masucci L, Quaranta G, Simonelli C, Lopetuso LR, Sanguinetti M, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions. Aliment Pharmacol Ther. 2018;48(2):152–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 62.Cheng Y-W, et al. Inpatient fecal microbiota transplant program decreases mortality and colectomy in severe and/or complicated Clostridium difficile infection: 101. Am J Gastroenterol. 2017;112:S48–50.Google Scholar
- 63.Cheng Y-W, et al. Fecal microbiota transplant decreases mortality in patients with refractory severe and severe complicated Clostridium difficile infection Not Eligible for Colectomy: 2017 Fellows-in-Training Award (Colon Category): 100. Am J Gastroenterol. 2017;112:S48–50.Google Scholar